Catalog No.
DHB94403
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1, kappa
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
TNF, Tumor necrosis factor ligand superfamily member 2, N-terminal fragment, ICD2, NTF, TNF-a, TNF-alpha, Tumor necrosis factor, TNFSF2, TNFA, Cachectin, ICD1
Concentration
1.2 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01375
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
TA-650, cA2, CAS: 170277-31-3
Clone ID
Infliximab
Note
For research use only. Not suitable for clinical or therapeutic use.
Long-Term Response Durability of Infliximab for Pediatric Inflammatory Bowel Disease in Japan: A Single Center Experience., PMID:40396153
Immunomodulatory Therapy Discontinuation for Reasons Other Than Efficacy in the Treatment of Ocular Inflammation., PMID:40397798
PErsistence and safety of subcutaneous infliximab 1 year after switch from intravenous route in IBD patients in REMission., PMID:40398832
The Incidence and Management of TNF-α Inhibitor Induced Paradoxical Psoriasis in Children With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis., PMID:40400050
Effects of infliximab infusion on clinical symptom scores and serum cytokines in patients with inflammatory bowel disease., PMID:40400059
Ustekinumab in the Treatment of Crohn's Disease-A Narrative Review on Clinical Efficacy and Safety Profile., PMID:40407511
Network Meta-Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis., PMID:40407729
Case report: Spontaneous splenic rupture concomitant with serum sickness induced by infliximab., PMID:40410001
Skin lesions and chest pain in a patient with Crohn's disease., PMID:40413034
A 30-year experience in neuro-Behçet disease., PMID:40414042
Exploring infliximab serum level variability in inflammatory bowel disease: Comprehensive analysis of patient subgroups and treatment outcomes "Infliximab trough levels variability in inflammatory bowel disease"., PMID:40414284
Association of the TNFRSF1B-rs1061622 variant with nonresponse to infliximab in ulcerative colitis., PMID:40414945
The position of anti-Tumor Necrosis Factor agents for the treatment of adult patients with Crohn's disease., PMID:40418234
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials., PMID:40418343
Predictors of drug survival of biologics in hidradenitis suppurativa: A systematic review and meta-analysis., PMID:40419221
Efficacy and safety of dual-targeted therapy for refractory inflammatory bowel disease: a retrospective case series from three tertiary general hospitals in China., PMID:40421289
Obinutuzumab-Induced Inflammatory Bowel Disease-Like Colitis., PMID:40421460
Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System., PMID:40426835
The Effects of the Biological Agents Infliximab, Vedolizumab, and Ustekinumab on Intestinal Anastomosis: An Experimental Study in Rats., PMID:40426907
Optimizing Biologic Therapy for the Prevention of Post-Operative Recurrence in Crohn's Disease: Current Evidence and Future Perspectives., PMID:40427059
JAK-STAT inhibitors in noninfectious uveitis - A review., PMID:40434456
Peripheral neuropathies associated with anti-tnf-α treatments: a systematic review and proposed recommendations., PMID:40447953
Treatment of Autoimmune Enteropathy With Vedolizumab., PMID:40452653
Higher induction and maintenance infliximab trough levels are associated with radiological perianal fistula healing in pediatric patients with Crohn's disease., PMID:40453222
Switching from intravenous to subcutaneous infliximab in patients with immune mediated diseases in clinical remission., PMID:40454138
Machine Learning Modeling for Predicting Infliximab Pharmacokinetics in Pediatric and Young Adult Patients With Crohn Disease: Leveraging Ensemble Modeling With Synthetic and Real-World Data., PMID:40459932
Comment on a Risk Stratification Tool for Relapse After Intravenous-to-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases., PMID:40464796
Infliximab-Induced Immune Thrombocytopenic Purpura in an Ulcerative Colitis Patient., PMID:40469247
Pharmacogenomics of TNF inhibitors., PMID:40469293
Anti-tumor Necrosis Factor-Alpha (TNF-α)-Induced Hypertrophic Lichen Planus: A Case Report., PMID:40470457
Tumor necrosis factor α inhibitor-induced alopecia in pediatric patients: a cohort of 20 patients and review of the literature., PMID:40481366
Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data., PMID:40481399
Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction., PMID:40484132
Clinical spectrum of acute severe ulcerative colitis in the biologic era: a prospective cohort study from India., PMID:40485102
Drug survival, long-term safety and efficacy of anti-TNF-alpha biosimilars: a monocentric retrospective study., PMID:40485573
Efficacy and Safety of Vedolizumab with Glucocorticoids vs Infliximabin Severe Ulcerative Colitis: A Retrospective Study., PMID:40487981
Infliximab Pharmacokinetics, Dosing, and Response in Hospitalized Patients with COVID-19 Pneumonia: A Secondary Analysis of a Multinational Randomized Clinical Trial (ACTIV-1 IM)., PMID:40488513
Metabolism and Response to Stress Gene Signatures Reveal Ulcerative Colitis Heterogeneity and Identify Patients With Increased Response to Therapy., PMID:40488582
Bibliometric analysis of global research trends on ultrasound in inflammatory bowel disease: A quickly developing field., PMID:40489862
Development of thymoma without myasthenia gravis in a patient with radiographic axial spondyloarthritis treated with tumor necrosis factor-α inhibitors., PMID:40491307
Clinical characteristics and treatment of infantile Takayasu arteritis in the Chinese Han population: a single-center study., PMID:40495185
Upadacitinib for refractory Behçet's disease with myelodysplastic syndrome and trisomy 8/9: a case report and mechanistic insights., PMID:40496858
The Use of Intravenous Infliximab to Treat Cancer Related Fistulae: A Case Report in Home-Based Palliative Care Improving Quality of Life and Closure., PMID:40498467
Which first? Surgery or biologic therapy for ileocolic Crohn's disease in the real world., PMID:40498697
Comparative effectiveness of ustekinumab versus infliximab in the management of perianal fistulizing Crohn's disease: a retrospective study in China., PMID:40499579
Serial 18F-Fluorodeoxyglucose Positron Emission Tomography to Assess the Efficacy of Infliximab in Steroid Refractory Cardiac Sarcoidosis., PMID:40499889
Curcumin-QingDai Combination as Treatment for Crohn's Disease: A Case Report., PMID:40503450
Post-traumatic ileal stenosis: a rare entity not to be confused with Crohn's disease., PMID:40503976
Effectiveness and Safety of Advanced Dual-Targeted Therapy in Refractory Perianal Crohn's Disease., PMID:40504122
Magnetic resonance spectroscopy biomarkers of anti-inflammatory interventions in mood disorders: A systematic review of clinical trials., PMID:40505984
For research use only. Not for human or drug use.
